

# BetterLife Pharma Inc

09:10 04 Jun 2020

## BetterLife Pharma secures support of Altum shareholders in proposed acquisition

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) has said it is making good progress in its proposed acquisition of Canada's Altum Pharmaceuticals Inc.

The Vancouver-based company told shareholders Thursday it has secured hard lock-up agreements from a majority of Altum's shareholders, clearing a path to finalizing the deal. Around 67% of Altum shareholders have agreed to the share lock-up.

Altum's drug pipeline includes lead product AP-003, an inhalation formulation that could represent a potential treatment against coronavirus (COVID-19) as it shows effectiveness in slowing viral replication. Under the agreement, BetterLife will acquire worldwide rights to commercialize and sell AP-003.

### READ: Coronavirus: What's happening in the labs of pharma companies worldwide

BetterLife said it had secured the lockup from Altum shareholders because it had reason to believe that the independent members of the board of Altum were attempting to cancel the licensing agreement.

In a statement, Robert Metcalfe, lead director of BetterLife told investors: "I am very pleased that such an overwhelming number of the Altum shareholders have decided to take these actions to express their support and commitment to the merger with BetterLife so that we may work together expeditiously on AP-003 so that we may better understand its potential as a COVID-19 treatment for the benefit of patients and for society at large."

### Deal terms

As outlined in the term sheet, BetterLife will issue 4.582 shares in the company in exchange for one Altum share in a deal worth approximately C\$36.1 million as of May 25, 2020.

According to the pharmaceutical company, BetterLife and certain Altum board members could not agree on terms despite the fact that the lock-up agreements given to BetterLife satisfied the legal test to acquire Altum.

The proposed acquisition is subject to the receipt of all required approvals and due diligence. If successful, Altum will become a wholly-owned subsidiary of BetterLife, which would commercialize AP-003 without restriction and without further payments or licensing obligations to Altum.

BetterLife is a biopharmaceutical company engaged in the development and commercialization of patented, differentiated and premium quality nutraceuticals and pharmaceuticals.

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

**Price:** 0.6914

**Market Cap:** \$25.88 m

### 1 Year Share Price Graph



December 2019 May 2020 December 20

### Share Information

**Code:** BETRF

**Listing:** OTCQB

|                |             |            |
|----------------|-------------|------------|
| <b>52 week</b> | <b>High</b> | <b>Low</b> |
|                | 2.21        | 0.0993     |

**Sector:** Pharma & Biotech

**Website:** [abetterlifepharma.com](http://abetterlifepharma.com)

### Company Synopsis:

*BLife Therapeutics, a wholly-owned subsidiary of BetterLife Pharma Inc., is focused on the development of its patent pending Interferon formula, AP-003, for the treatment and prevention of severe COVID-19 disease. Its parent, Better Life Pharma Inc.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).